ASCO Preview: Five Presentations To Watch Out For

AstraZeneca’s data showcase its grand strategy in lung cancer, while a trial from Gilead could provide valuable learnings for anti-TROP2 antibodies as they become more competitive - not only on efficacy, but also on safety. J&J and Legend, meanwhile, are nipping at BMS and 2seventy’s heels.

• Source: Scrip

The American Society of Clinical Oncology 2024 conference begins shortly, with thousands of abstracts slated for presentation in poster and oral sessions. Scrip will be on the ground for the meeting, taking place 31 May-4 June in Chicago, to cover the most important presentations, including multiple lung cancer datasets, the increasingly competitive space of antibody-drug conjugates (ADCs) targeting TROP2, a cancer vaccine in melanoma and cell therapy for multiple myeloma and other cancers.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from ASCO

TIL The CARs Come Home: How Cell Therapy’s Solid Tumor Future Is Shaping Up

 

Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.

Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease

 

The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers. 

ASCO 2024 Wrap-Up Podcast

 

Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting.   

China Biotech Podcast: BIOSECURE Act Updates ASCO Highlights

 

US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.

More from Conferences

Lexicon Has A Lot Riding On LX9211 Phase IIb Readout In Pain

 

CEO Mike Exton talked to Scrip about moving the company forward after a disappointingly disruptive 2024.

Reflections From Biotech Leader John Maraganore

 

The founder and director of City Therapeutics and founding CEO of Alnylam discussed pressing issues facing the biotech sector in a fireside chat at the recent BIO CEO & Investor Conference.

M&A Takeoff May Be Delayed, Experts Predict

 

All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.